Literature DB >> 28947933

Modulating GluN2B for the Treatment of Neurological and Psychiatric Disorders.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2017        PMID： 28947933      PMCID： PMC5601381          DOI： 10.1021/acsmedchemlett.7b00309

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.

Authors:  Dénes Zádori; Gábor Veres; Levente Szalárdy; Péter Klivényi; József Toldi; László Vécsei
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 2.  Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates.

Authors:  Min Wang; Amy F T Arnsten
Journal:  Neurosci Bull       Date:  2015-03-09       Impact factor: 5.203

3.  Modulating synaptic NMDA receptors.

Authors:  Kenneth R Tovar; Gary L Westbrook
Journal:  Neuropharmacology       Date:  2016-08-23       Impact factor: 5.250

Review 4.  Human GRIN2B variants in neurodevelopmental disorders.

Authors:  Chun Hu; Wenjuan Chen; Scott J Myers; Hongjie Yuan; Stephen F Traynelis
Journal:  J Pharmacol Sci       Date:  2016-10-19       Impact factor: 3.337

Review 5.  D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.

Authors:  Donald C Goff
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.